Company Analysis
Sign in

Barinthus Biotherapeutics plc (BRNS)

BRNS · Pharmaceutical Preparations · Germantown, MD · filing with the SEC since 2020
Full chart Alerts Compare
Grade4.5
◀ Past 4.8● Present 5.1▶ Future 3.7
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Income statement, as filed

In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Report filedMar 13, 2026Mar 20, 2025Mar 20, 2024Mar 24, 2023Mar 25, 2022·
Revenue014,96980244,7032684,821
Research and development25,56442,23644,87442,35020,37114,387
General and administrative40,83029,67039,8426,39425,11810,480
Total operating expenses71,06184,11584,71648,74445,48924,867
Operating income-70,555-67,970-83,914-4,041-45,221-20,046
Interest expense515328192,6683,600
Interest and investment income1,9572,6782,8773,10320
Other income (expense), net161351,08256733242
Total non-operating income (expense)3,9226,7437,3924,891-5,9192,208
Income before income taxes-66,633-61,227-76,522850-51,140·
Income tax expense-175-44-3,075-4,471-2895
Net income including non-controlling interests-66,458-61,183-73,4475,321-51,112-17,933
Net income to non-controlling interests-30-109-100-21-247-227
Net income-66,428-61,074-73,3475,342-50,865-17,706
Earnings per share, basic-1.64-1.55-1.910.14-1.96-2.24
Earnings per share, diluted-1.64-1.55-1.910.14-1.96-2.24
Weighted average shares, basic40,527,21839,348,24038,386,49137,248,12625,894,3757,904,529
Weighted average shares, diluted40,527,21839,348,24038,386,49138,169,30725,894,3757,904,529
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense
General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense
Total operating expenses the running costs togetherus-gaap:OperatingExpenses
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Interest expense what its borrowing costus-gaap:InterestExpenseNonoperating
us-gaap:InterestExpense
Interest and investment income what its cash and investments earnedus-gaap:InvestmentIncomeInterest
Other income (expense), net gains and costs outside the businessus-gaap:OtherNonoperatingIncomeExpense
Total non-operating income (expense) everything outside the business, togetherus-gaap:NonoperatingIncomeExpense
Income before income taxes profit before taxus-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit
Net income including non-controlling interests the whole group's profit, minority holders' share includedus-gaap:ProfitLoss
Net income to non-controlling interests the share that belongs to minority holdersus-gaap:NetIncomeLossAttributableToNoncontrollingInterest
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
SI Assistanton BRNS · research, not advice